Medical Doctor Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Neal Chawla

Hematology & Oncology Santa Monica, CA Medical Doctor

NPI 1669906665 CMS profile 11626144

2811 Wilshire Blvd Ste 414, Santa Monica, CA 90403

Open in the dashboard

General payments

$6,577

189 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$59,391 paid to institutions, not to them · program year 2025

Through program year 2025, Neal Chawla of Santa Monica, CA is reported in the CMS Open Payments database as having received $6,577 across 189 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $59,391 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 64th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,144 142
2024 General $1,433 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Neal Chawla
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Neal Chawla were reported at $5,144. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Neal Chawla Hematology & Oncology median Middle half National median
2019 $0 $529 $121–$2,516 $163
2020 $0 $339 $82–$2,213 $114
2021 $0 $263 $49–$1,965 $132
2022 $0 $416 $103–$2,395 $149
2023 $0 $542 $125–$2,646 $160
2024 $1,433 $692 $141–$3,008 $164
2025 $5,144 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $1,169 7 payments
  2. Ipsen Biopharmaceuticals, Inc $538 11 payments
  3. Aadi Bioscience, Inc. $422 9 payments
  4. Astellas Pharma US Inc $419 13 payments
  5. AstraZeneca Pharmaceuticals LP $364 14 payments
  6. Daiichi Sankyo Inc. $324 16 payments
  7. Incyte Corporation $313 12 payments
  8. E.R. Squibb & Sons, L.L.C. $301 16 payments
  9. Merck Sharp & Dohme Corporation $244 9 payments
  10. AbbVie, Inc. $219 5 payments
  11. Other $2,264 77 payments

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $5,179 183 payments
  2. Consulting Fee $1,001 1 payment
  3. Education $373 4 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24 1 payment
Products named General payments · program years 2024–2025
  1. Vitrakvi $1,115 5 payments
  2. TAZVERIK $448 10 payments
  3. Fyarro $422 9 payments
  4. ENHERTU Oncology $302 14 payments
  5. KEYTRUDA $244 9 payments
  6. OPDIVO $242 13 payments
  7. JAKAFI $233 9 payments
  8. ELAHERE $196 4 payments
  9. CABOMETYX $175 1 payment
  10. ENHERTU Oncology $173 7 payments
  11. Other $3,223 122 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

189 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record